# SLE - Renal and Hematologic Manifestations

## Introduction

Lupus nephritis affects 40 to 60 percent of patients with systemic lupus erythematosus and remains a major driver of morbidity and mortality in this disease. Hematologic manifestations, including cytopenias, thrombotic microangiopathy, and macrophage activation syndrome, are among the most common features of SLE and frequently influence management decisions. Both renal and hematologic involvement carry significant prognostic implications and dictate the intensity of immunosuppressive treatment. Recent landmark trials, including AURORA, BLISS-LN, and NOBILITY, have substantially expanded the therapeutic armamentarium for lupus nephritis and reshaped current treatment paradigms.

## Lupus Nephritis

### Epidemiology and Risk Factors

Lupus nephritis develops in 40 to 60 percent of SLE patients, with significantly higher prevalence and severity in Black, Hispanic, and Asian populations. Renal involvement most commonly presents within the first five years of SLE diagnosis. Risk factors for the development of severe nephritis include male sex, young age at disease onset, Black or Hispanic ethnicity, anti-dsDNA antibody positivity, persistently low complement levels, and the presence of anti-C1q antibodies. Despite advances in therapy, end-stage renal disease develops in 10 to 15 percent of patients with lupus nephritis, with five-year renal survival rates of approximately 80 percent under modern treatment protocols.

### Clinical Presentation

Lupus nephritis is often asymptomatic in its early stages, detected only through screening urinalysis and renal function testing. Proteinuria is the hallmark finding, reaching nephrotic-range levels exceeding 3.5 grams per day in proliferative and membranous classes. Active urinary sediment, characterized by dysmorphic red blood cells and red blood cell casts, is indicative of proliferative nephritis and demands urgent evaluation. Hypertension is a common accompaniment and requires aggressive blood pressure control with a target below 130/80 mmHg. Edema and full nephrotic syndrome are characteristic of class V membranous nephritis. Rapidly progressive glomerulonephritis with crescentic disease and rapid decline in glomerular filtration rate represents a medical emergency. Renal vein thrombosis should be considered in patients with nephrotic syndrome and concomitant antiphospholipid antibodies.

### Indications for Renal Biopsy

Renal biopsy is the definitive diagnostic procedure for lupus nephritis and is essential for guiding therapy and establishing prognosis. It is indicated when proteinuria exceeds 0.5 grams per 24 hours (or a urine protein-to-creatinine ratio above 0.5), when active urinary sediment is present even with lower proteinuria levels, or when an unexplained rise in serum creatinine occurs. Repeat biopsy should be considered in cases of treatment failure, disease flare after remission, or a changing clinical picture, as the histologic class may evolve over time. The clinical presentation alone cannot reliably predict the histologic class, making biopsy indispensable for treatment planning.

### ISN/RPS Classification (2003, revised 2018)

The International Society of Nephrology/Renal Pathology Society classification system provides the framework for categorizing lupus nephritis histology and guiding therapeutic decisions. Class I, minimal mesangial nephritis, shows normal findings on light microscopy with mesangial immune deposits on immunofluorescence and electron microscopy, and does not require specific treatment. Class II, mesangial proliferative nephritis, demonstrates mesangial hypercellularity with mild proteinuria and is managed conservatively.

Class III, focal proliferative nephritis, involves fewer than 50 percent of glomeruli with subendothelial deposits and requires immunosuppressive therapy. It is further subclassified into active (III(A)), active and chronic (III(A/C)), and chronic (III(C)) lesions. Class IV, diffuse proliferative nephritis, is the most common and most severe form, affecting 50 percent or more of glomeruli. This class accounts for 35 to 60 percent of lupus nephritis cases and is characterized by wire-loop deposits, subendothelial deposits, and endocapillary proliferation. The immunofluorescence pattern is distinctive, with "full house" staining showing deposition of IgG, IgA, IgM, C3, and C1q. Class IV is subdivided into segmental (IV-S) and global (IV-G) patterns.

Class V, membranous nephritis, presents with subepithelial deposits and nephrotic syndrome and may coexist with Class III or IV changes. Class VI, advanced sclerotic nephritis, is defined by more than 90 percent globally sclerosed glomeruli, represents irreversible damage, and is not amenable to immunosuppressive therapy.

The Activity Index (AI) and Chronicity Index (CI) provide semi-quantitative assessment of active inflammation and chronic damage, respectively. A high Chronicity Index, particularly the presence of fibrous crescents, tubular atrophy, and interstitial fibrosis, is the strongest histologic predictor of poor long-term renal outcome, while the Activity Index guides the intensity of immunosuppressive therapy.

<image>A detailed histopathological comparison of the ISN/RPS lupus nephritis classes (I through VI) shown as kidney biopsy illustrations. For each class, show a representative glomerulus under light microscopy with key features labeled: Class I (normal glomerulus, mesangial deposits on IF), Class II (mesangial hypercellularity), Class III (focal endocapillary proliferation in <50% of glomeruli with segmental necrosis), Class IV (diffuse endocapillary proliferation with wire-loop deposits, crescents), Class V (thickened GBM with subepithelial deposits shown as spikes on silver stain), Class VI (globally sclerosed glomerulus with interstitial fibrosis). Include an inset showing the "full house" immunofluorescence pattern for Class IV with IgG, IgA, IgM, C3, and C1q all positive. Use standard histology colors.</image>

### Treatment of Lupus Nephritis

#### Class III/IV (Proliferative) Nephritis

The treatment of proliferative lupus nephritis has been transformed by recent clinical trials and now follows a multi-drug induction strategy. Induction therapy spans six to twelve months and includes a backbone of either mycophenolate mofetil or intravenous cyclophosphamide combined with glucocorticoids and, increasingly, add-on targeted therapies.

Mycophenolate mofetil at 2 to 3 grams per day was established as non-inferior to intravenous cyclophosphamide in the ALMS trial and is preferred in Black and Hispanic patients based on subgroup analyses from the ASPREVA/ALMS studies demonstrating superior outcomes in these populations. Intravenous cyclophosphamide following the Euro-Lupus protocol of 500 milligrams every two weeks for six doses was shown to be non-inferior to the high-dose NIH protocol (0.5 to 1 gram per square meter monthly for six doses) with substantially lower toxicity, making the low-dose Euro-Lupus regimen the preferred cyclophosphamide approach for most patients. The high-dose NIH protocol is reserved for severe proliferative disease with crescents. Glucocorticoids are administered as intravenous methylprednisolone 250 to 1000 milligrams for three days, followed by oral prednisone 0.5 to 1 milligram per kilogram with a taper over three to six months. The 2023 EULAR/ERA-EDTA guidelines recommend rapid taper to 5 milligrams per day or less by three months.

Add-on therapies have become the new standard of care. Belimumab, an anti-BAFF monoclonal antibody, was studied in the BLISS-LN trial, where its addition to standard therapy improved renal response rates (43 percent versus 32 percent at two years) and reduced renal-related events. Voclosporin, a novel calcineurin inhibitor, was studied in the AURORA trial at a dose of 23.4 milligrams twice daily added to mycophenolate mofetil and low-dose glucocorticoids, improving complete renal response from 23 percent to 41 percent at one year. The 2023 KDIGO and EULAR guidelines now recommend adding either belimumab or voclosporin to standard induction therapy. Obinutuzumab, a type II anti-CD20 monoclonal antibody studied in the NOBILITY trial, showed improved complete renal response compared to placebo at 76 weeks and is under further investigation.

Maintenance therapy follows induction and continues for a minimum of three to five years, or longer in patients at high risk for relapse. Mycophenolate mofetil at 1 to 2 grams per day is preferred based on the ALMS maintenance study, which demonstrated superiority of MMF over azathioprine. Continued belimumab during maintenance further reduces relapse risk.

| Trial | Drug | Design | Key Finding | Impact on Practice |
|-------|------|--------|-------------|-------------------|
| ALMS (induction) | MMF vs IV CYC | RCT, non-inferiority | MMF non-inferior to IV CYC; superior in Black/Hispanic subgroups | MMF preferred for induction, especially in Black/Hispanic patients |
| Euro-Lupus | Low-dose IV CYC (500 mg q2wk x6) vs NIH high-dose | RCT | Low-dose non-inferior with fewer side effects | Low-dose Euro-Lupus protocol preferred over NIH protocol |
| ALMS (maintenance) | MMF vs AZA | RCT | MMF superior to AZA for maintenance | MMF preferred for maintenance therapy |
| BLISS-LN | Belimumab + standard therapy | RCT, placebo-controlled | 43% vs 32% renal response at 2 years | Belimumab added to standard induction/maintenance |
| AURORA 1 | Voclosporin + MMF + low-dose GC | RCT, placebo-controlled | 41% vs 23% complete renal response at 1 year | Voclosporin added to standard induction |
| NOBILITY | Obinutuzumab + standard therapy | Phase II RCT | Improved complete renal response at 76 weeks | Under further investigation |
| LUNAR | Rituximab + standard therapy | RCT (negative) | Did not meet primary endpoint | Rituximab used off-label for refractory cases despite negative trial |

#### Class V (Membranous) Nephritis

Isolated Class V membranous nephritis with subnephrotic proteinuria is managed with hydroxychloroquine and ACE inhibitors or angiotensin receptor blockers, with careful monitoring. Nephrotic-range proteinuria warrants treatment with mycophenolate mofetil or a calcineurin inhibitor (tacrolimus or voclosporin) combined with glucocorticoids. When Class V coexists with Class III or IV changes, treatment follows the more aggressive proliferative nephritis protocol.

#### Refractory/Relapsing Nephritis

Rituximab, despite the technically negative LUNAR trial that did not meet its primary endpoint, has substantial observational support and is used in clinical practice for refractory cases, supported by data from the RING study. Switching between mycophenolate mofetil and cyclophosphamide is an accepted approach. The multitarget regimen combining tacrolimus, mycophenolate mofetil, and glucocorticoids, supported primarily by Chinese clinical data, is effective particularly in combined Class V plus III/IV disease. Repeat biopsy is essential in refractory cases to distinguish active inflammation amenable to immunosuppression from chronic damage that would not benefit from further treatment escalation.

### Monitoring and Response Criteria

Complete renal response is defined as a urine protein-to-creatinine ratio below 0.5 to 0.7, normal or stable glomerular filtration rate, and inactive urinary sediment. Partial renal response requires at least a 50 percent reduction in proteinuria with stable or improved GFR. Monitoring should include urine protein-to-creatinine ratio, serum creatinine, and urinalysis every one to three months, with anti-dsDNA and complement levels every three months. Repeat biopsy at one year to assess treatment response is recommended by EULAR.

## Hematologic Manifestations

### Cytopenias in SLE

#### Autoimmune Hemolytic Anemia (AIHA)

Autoimmune hemolytic anemia occurs in 5 to 10 percent of SLE patients and is typically a warm AIHA mediated by IgG antibodies. The diagnosis is established by a positive direct antiglobulin test (Coombs test) in combination with markers of hemolysis: elevated lactate dehydrogenase, low haptoglobin, elevated indirect bilirubin, and reticulocytosis. Spherocytes on peripheral smear are a characteristic finding. First-line treatment is prednisone at 1 milligram per kilogram per day. For refractory AIHA, options include mycophenolate mofetil, azathioprine, rituximab, and danazol. Evans syndrome, the combination of AIHA and immune thrombocytopenia, carries a worse prognosis.

#### Immune Thrombocytopenia

Immune thrombocytopenia affects 10 to 40 percent of SLE patients and may be the presenting feature of the disease. Mild thrombocytopenia above 50,000 per microliter often does not require treatment. Severe thrombocytopenia below 30,000 or active bleeding warrants treatment with prednisone at 1 milligram per kilogram per day and intravenous immunoglobulin at 1 gram per kilogram for two days. Rituximab is the preferred agent for refractory cases, with additional options including mycophenolate mofetil, azathioprine, thrombopoietin receptor agonists (eltrombopag, romiplostim), and splenectomy as a last resort. It is essential to distinguish immune thrombocytopenia from thrombotic thrombocytopenic purpura (TTP) and thrombotic microangiopathy by checking ADAMTS13 activity, examining for schistocytes, and assessing LDH and renal function.

#### Leukopenia/Lymphopenia

Lymphopenia below 1000 per microliter is the most common hematologic finding in SLE and correlates with disease activity. Anti-lymphocyte antibodies drive lymphocyte destruction. Neutropenia is less common and usually mild; drug-induced causes from cyclophosphamide, mycophenolate, or azathioprine must be considered. Severe neutropenia below 500 per microliter may require granulocyte colony-stimulating factor, and macrophage activation syndrome or hemophagocytic lymphohistiocytosis should be excluded.

### Thrombotic Microangiopathy (TMA) in SLE

Thrombotic microangiopathy in SLE requires careful differentiation among SLE-associated TMA, thrombotic thrombocytopenic purpura, and complement-mediated TMA. ADAMTS13 activity below 10 percent is diagnostic of TTP and mandates treatment with plasma exchange and caplacizumab. ADAMTS13 activity above 10 percent suggests complement-mediated TMA, for which eculizumab may be effective. Renal TMA may coexist with lupus nephritis and is associated with antiphospholipid antibodies and anti-ADAMTS13 antibodies.

### Macrophage Activation Syndrome (MAS/HLH)

Macrophage activation syndrome, a form of hemophagocytic lymphohistiocytosis, occurs in 0.9 to 4.6 percent of SLE patients and is frequently underrecognized. It may be triggered by disease flare, infection (especially viral), or medication changes. The clinical features include high fever, marked hyperferritinemia (levels exceeding 10,000 nanograms per milliliter are suggestive), cytopenias, hypertriglyceridemia, hypofibrinogenemia, elevated soluble IL-2 receptor, and hemophagocytosis on bone marrow biopsy. A paradoxically low ESR in the setting of high CRP occurs because fibrinogen, the major determinant of ESR, is consumed. The ferritin-to-ESR ratio exceeding 21 suggests MAS over a SLE flare. Treatment involves high-dose glucocorticoids (methylprednisolone 1 gram for three to five days), cyclosporine, intravenous immunoglobulin, etoposide, and anakinra, along with treatment of the underlying trigger.

<image>A diagnostic algorithm for evaluating cytopenias in SLE. Start with "SLE patient with new cytopenias" and branch into three pathways: (1) Anemia pathway: check reticulocyte count, DAT, LDH, haptoglobin → if DAT positive with hemolysis markers → AIHA; if schistocytes present → check ADAMTS13 → TTP vs complement-mediated TMA. (2) Thrombocytopenia pathway: check peripheral smear, ADAMTS13, coagulation studies → if isolated thrombocytopenia with normal smear → immune thrombocytopenia; if schistocytes → TMA/TTP; if pancytopenia with hyperferritinemia → evaluate for MAS/HLH. (3) Leukopenia pathway: check differential → lymphopenia (anti-lymphocyte antibodies, active SLE) vs neutropenia (drug-induced vs autoimmune). Include treatment options at each endpoint.</image>

### Antiphospholipid-Related Hematologic Complications

Moderate thrombocytopenia in the range of 50,000 to 100,000 per microliter occurs in 20 to 30 percent of antiphospholipid antibody-positive SLE patients. Catastrophic antiphospholipid syndrome (CAPS), characterized by multiorgan thrombotic microangiopathy involving three or more organs within one week, is a life-threatening emergency with treatment consisting of anticoagulation, glucocorticoids, plasma exchange with or without intravenous immunoglobulin, and rituximab or eculizumab for refractory cases. Antiphospholipid nephropathy is histologically distinct from immune complex-mediated lupus nephritis, presenting with thrombotic lesions on biopsy, and the two entities can coexist.

## Lupus and the Kidney: Beyond Nephritis

Renal involvement in SLE extends beyond glomerulonephritis. Tubulointerstitial nephritis can occur independently of glomerular disease. Renal artery stenosis may develop in antiphospholipid antibody-positive patients. Drug-induced nephrotoxicity from NSAIDs and calcineurin inhibitors (tacrolimus, voclosporin) requires monitoring of GFR. Lupus nephritis recurrence after kidney transplantation occurs at a rate of approximately 10 percent but is generally milder than native disease.

## Key Clinical Pearls

- "Full house" immunofluorescence (IgG, IgA, IgM, C3, C1q) is characteristic of lupus nephritis class IV
- Euro-Lupus low-dose IV CYC protocol is non-inferior to NIH high-dose protocol with fewer side effects
- Belimumab and voclosporin are now add-on standard of care for proliferative lupus nephritis per KDIGO 2023
- Ferritin >10,000 with a paradoxically low ESR should raise suspicion for MAS/HLH in SLE
- Always check ADAMTS13 in SLE patients with thrombocytopenia and schistocytes to distinguish TTP from SLE-TMA
- Chronicity index on renal biopsy (not activity index) is the strongest histologic predictor of long-term renal outcome

<image>A treatment timeline diagram for Class IV lupus nephritis showing the current standard of care. Show a horizontal timeline from diagnosis through induction (months 0-6) and maintenance (months 6 to 3-5 years). During induction, show: IV methylprednisolone pulses (days 1-3), oral prednisone taper (starting 0.5-1 mg/kg, tapering to ≤5 mg by 3 months), MMF 2-3 g/day (or Euro-Lupus CYC as alternative), plus add-on therapy (belimumab IV/SC or voclosporin 23.4 mg BID). During maintenance, show: MMF 1-2 g/day, low-dose prednisone (≤5 mg or off), continued belimumab, HCQ throughout. Mark assessment points at 3, 6, and 12 months with target response criteria (complete vs partial renal response). Include a decision box for "inadequate response at 6 months" leading to re-biopsy and treatment change options.</image>

## References
1. Bajema IM, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis. Kidney Int. 2018;93(4):789-796.
2. Furie R, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis (BLISS-LN). N Engl J Med. 2020;383(12):1117-1128.
3. Rovin BH, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1). Lancet. 2021;397(10289):2070-2080.
4. Houssiau FA, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2002;46(8):2121-2131.
5. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1-S69.